MoneyWorks4Me

Glenmark Pharmaceuticals informs about media release

21 Mar 2026 Evaluate
Glenmark Pharmaceuticals has informed that the company research-led, global pharmaceutical company, today announced the launch of GLIPIQ® (semaglutide) in India for the management of Type 2 Diabetes Mellitus (T2DM), setting a new benchmark in affordability for GLP-1 therapy and expanding access to advanced diabetes treatment for patients. The company has attached media release.

The above information is a part of company’s filings submitted to BSE.
Peers
Company Name CMP
Sun Pharma. Inds. 1835.00
Dr. Reddys Labs. 1149.75
Cipla 1361.00
Lupin 2055.35
Zydus Lifesciences 1099.00
View more..